Close



Apr 9, 2024 06:36AM
Apr 9, 2024 05:12AM
Apr 8, 2024 06:34AM
Apr 8, 2024 06:30AM
Mar 26, 2024 08:30AM
Mar 12, 2024 08:30AM
Nov 7, 2023 08:30AM Inozyme Pharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights
Oct 26, 2023 08:30AM
Oct 10, 2023 08:30AM
Oct 6, 2023 08:30AM
Sep 26, 2023 07:30AM
Sep 26, 2023 07:30AM
Sep 20, 2023 08:30AM
Aug 8, 2023 08:30AM Inozyme Pharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights
Jul 26, 2023 07:31AM
Jul 26, 2023 07:30AM
Jul 19, 2023 08:30AM
Jun 27, 2023 08:30AM
May 9, 2023 08:30AM
Mar 22, 2023 08:30AM
Feb 16, 2023 07:30AM Inozyme Pharma (INZY) Reports Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701
Feb 16, 2023 07:30AM
Feb 6, 2023 07:30AM
Jan 9, 2023 08:30AM
Nov 10, 2022 08:30AM
Nov 3, 2022 07:30AM
Aug 15, 2022 07:30AM
Jul 26, 2022 07:30AM Inozyme Pharma Secures Flexible Debt Facility for up to $70 Million with K2 HealthVentures
Jul 19, 2022 04:30PM
Jul 19, 2022 04:30PM
Jun 16, 2022 07:30AM
Jun 7, 2022 07:31AM
Jun 7, 2022 07:30AM
May 10, 2022 07:30AM
Apr 12, 2022 07:31AM Inozyme Pharma Inc. (INZY) Doses First Patients in Phase 1/2 Clinical Trials in ABCC6 Deficiency and ENPP1 Deficiency
Apr 12, 2022 07:30AM
Apr 4, 2022 07:30AM
Apr 4, 2022 07:30AM
Mar 15, 2022 05:29PM
Mar 15, 2022 05:24PM
Mar 8, 2022 07:34AM
Mar 8, 2022 07:30AM Inozyme Pharma Strengthens Management Team with Two Executive Appointments
Feb 7, 2022 06:48AM
Nov 15, 2021 07:30AM
Nov 9, 2021 04:05PM
Oct 4, 2021 07:30AM
Aug 11, 2021 06:00AM
Jul 21, 2021 07:30AM
Jul 21, 2021 07:30AM Inozyme Pharma Receives Orphan Drug Designation for INZ-701 from the European Medicines Agency for the Treatment of ABCC6 Deficiency
Jul 13, 2021 07:30AM

251,395 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All